|
| 重组人干扰素α-1b联合大剂量丙种球蛋白治疗重症手足口病合并病毒性脑炎的疗效 |
| Effects of recombinant human interferon α-1b combined with high-dose gamma globulin on serum levels of T cell subsets and insulin-like growth factor -1 in children with severe hand-foot-mouth disease and viral encephalitis |
| 投稿时间：2018-09-12 |
| DOI：10.3969/j.issn.1000-0399.2019.04.010 |
| 中文关键词: 病毒性脑炎 手足口病 重组人干扰素α-1b 丙种球蛋白 胰岛素样生长因子-1 |
| 英文关键词: Viral encephalitis Hand-foot-mouth disease Recombinant human interferon α-1b Gamma globulin Insulin-like growth factor-1 |
| 基金项目:四川省卫生和计划生育委员会科研（项目编号：20150172） |
|
| 摘要点击次数: 1916 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 探究重组人干扰素α-1b联合大剂量丙种球蛋白治疗重症手足口病（HFMD）合并病毒性脑炎的临床效果。方法 选取2014年2月至2017年4月宜宾市第二人民医院收治135例HFMD并病毒性脑炎患儿，按随机数字表法分为对照A组（重组人干扰素α-1b）、对照B组（大剂量丙种球蛋白）及观察组（重组人干扰素α-1b+大剂量丙种球蛋白），各45例。比较三组患儿疗效、治疗后血清胰岛素样生长因子-1（IGF-1）、白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、S100B、神经特异性烯醇化酶（NSE）水平及血清T细胞亚群水平变化情况。结果 观察组总有效率（93.33%）高于对照A组、B组（73.33%、73.56%），差异有统计学意义（P<0.05）。治疗后，观察组CD3+、CD4+、CD4+/CD8+、CD8+改善程度大于对照A、B组，血清IGF-1、IL-6、TNF-α、S100B、NSE改善程度大于对照A、B组，差异均有统计学意义（P<0.05）。三组患儿不良反应发生率比较，差异无统计学意义（P>0.05）。结论 重组人干扰素α-1b联合大剂量丙种球蛋白治疗重症HFMD并病毒性脑炎患儿疗效显著，能显著提高患儿免疫功能，减轻机体炎性反应，缓解脑损伤，调节IGF-1水平。 |
| 英文摘要: |
| Objective To investigate the clinical effect of recombinant human interferon α-1b combined with high-dose gamma globulin on children with severe hand-foot-mouth disease (HFMD) and viral encephalitis. Methods A total of 135 children with HFMD and viral encephalitis from Feb 2014 to April 2017 in Yibin Second People's Hospital were randomly divided into control group A (recombinant human interferon α-1b) and control group B (high-dose gamma globulin) and observation group (recombinant human interferon α-1b + high-dose gamma globulin) according to the random number table method, with 45 cases in each group.The therapeutic effects, serum insulin-like growth factor-1 (IGF-1), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), S100B, neuro-specific enolase (NSE) levels and changes in serum T cell subsets were compared among the three groups. Results The total effective rate of observation group (93.33%) was higher than that of control group A and B (73.33%, 73.56%) (P<0.05). After treatment, the improvement of CD3+, CD4+, CD4+/CD8+ and CD8+ was higher than that of control group A and B (P<0.05); the improvement of serum IGF-1, IL-6, TNF-α, S100B and NSE in observation group was higher than that in control group A and B (P<0.05); there was no significant difference in the incidence of adverse reactions among three groups (P>0.05). Conclusions The clinical effect of children with severe HFMD and viral encephalitis treated by recombinant human interferon α-1b combined with high-dose gamma globulin is significant. It can significantly improve the immune function of the children, reduce the inflammatory response, alleviate brain damage and regulate the level of IGF-1. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
